JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 19, 2006; DOI: 10.1124/jpet.106.111351


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.106.111351v1
319/3/1200    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ge, Z.-D.
Right arrow Articles by Auchampach, J. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ge, Z.-D.
Right arrow Articles by Auchampach, J. A
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy
Hazardous Substances DB
*HISTAMINE


Received for publication July 21, 2006.
Revised September 16, 2006.
Accepted for publication September 18, 2006.

Cl-IB-MECA reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor

Zhi-Dong Ge 1, Jason N Peart 1, Tina C Wan 1, Laura M Kreckler 1, Marlene A Jacobson 2, Garrett J Gross 1, John A Auchampach 1*

1 Medical College of Wisconsin 2 Merck Research Laboratories

* Address correspondence to: E-mail: jauchamp{at}mcw.edu

Abstract

We used pharmacological agents and genetic methods to determine whether the potent A3 adenosine receptor (AR) agonist 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) protects against myocardial ischemia/reperfusion injury in mice via the A3AR or via interactions with other AR subtypes. Pretreating wild-type (WT) mice with Cl-IB-MECA reduced myocardial infarct size induced by 30 min of coronary occlusion and 24 h of reperfusion at doses (30 and 100 µg/kg) that concomitantly reduced blood pressure and stimulated systemic histamine release. The A3AR-selective antagonist MRS 1523, but not the A2AAAR antagonist ZM 241385, blocked the reduction in infarct size provided by Cl-IB-MECA, suggesting a mechanism involving the A3AR. To further examine the selectivity of Cl-IB-MECA, we assessed its cardioprotective effectiveness in A3AR gene 'knock-out' (A3KO) mice. Cl-IB-MECA did not reduce myocardial infarct size in A3KO mice in vivo and did not protect isolated perfused hearts obtained from A3KO mice from injury induced by global ischemia and reperfusion. Additional studies using WT mice treated with compound 48/80 to deplete mast cell contents excluded the possibility that Cl-IB-MECA was cardioprotective by releasing mediators from mast cells. These data demonstrate that Cl-IB-MECA protects against myocardial ischemia/reperfusion injury in mice principally by activating the A3AR.


Key words: adenosine, heart, infarction, ischemia, receptors, reperfusion


This article has been cited by other articles:


Home page
CirculationHome page
B. A. Rothermel and J. A. Hill
Adenosine A3 Receptor and Cardioprotection: Enticing, Enigmatic, Elusive
Circulation, October 21, 2008; 118(17): 1691 - 1693.
[Full Text] [PDF]


Home page
CirculationHome page
Z. Lu, J. Fassett, X. Xu, X. Hu, G. Zhu, J. French, P. Zhang, J. Schnermann, R. J. Bache, and Y. Chen
Adenosine A3 Receptor Deficiency Exerts Unanticipated Protective Effects on the Pressure-Overloaded Left Ventricle
Circulation, October 21, 2008; 118(17): 1713 - 1721.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. van der Hoeven, T. C. Wan, and J. A. Auchampach
Activation of the A3 Adenosine Receptor Suppresses Superoxide Production and Chemotaxis of Mouse Bone Marrow Neutrophils
Mol. Pharmacol., September 1, 2008; 74(3): 685 - 696.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. C. Wan, Z.-D. Ge, A. Tampo, Y. Mio, M. W. Bienengraeber, W. R. Tracey, G. J. Gross, W.-M. Kwok, and J. A. Auchampach
The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 234 - 243.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. R. Ansari, A. Nadeem, S. L. Tilley, and S. J. Mustafa
Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta
Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3448 - H3455.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Zheng, R. Wang, E. Zambraski, D. Wu, K. A. Jacobson, and B. T. Liang
Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury
Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3685 - H3691.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Zhu, P. A. Hofmann, and J. K. Buolamwini
Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2921 - H2926.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.